AI Article Synopsis
- - The study examined the effectiveness of intermittent maintenance chemotherapy in advanced ovarian cancer patients and included 25 participants treated between 1991 and 1998 after they had surgery and standard chemotherapy.
- - Results showed that the median progression-free interval (PFI) for the intermittent chemotherapy group was 25 months compared to 18 months in the control group, indicating a significant improvement (P = 0.0124).
- - The findings suggest that intermittent maintenance chemotherapy could be beneficial for patients who achieve a disease-free status after initial treatment, as it led to longer PFI and favorable survival rates.
Article Abstract
Background: The purpose of this study was to report the duration of the progression-free interval (PFI) in advanced ovarian cancer patients who were treated with intermittent maintenance chemotherapy.
Methods: Between 1991 and 1998, 25 patients with stage III or IV ovarian cancer were enrolled in a trial of intermittent maintenance chemotherapy. All patients underwent cytoreduction surgery, and received adjuvant chemotherapy, after which they were treated with intermittent maintenance chemotherapy every 3 to 4 months for 2 years.
Results: The median PFI in the 25 women in the intermittent chemotherapy group was 25 months, while in the 32 patients in the control group it was 18 months (P = 0.0124). The median survival of women treated with the intermittent chemotherapy was 34 months, and for the control group patients, it was 35 months (P = 0.0672). Multivariate analysis in the intermittent chemotherapy group revealed that the only factor that correlated significantly with PFI was the status after adjuvant chemotherapy (P = 0.0137). In patients with no evidence of disease after the adjuvant chemotherapy, the median survival was 39 months in the intermittent chemotherapy group, and 35 months in the control group (P = 0.0156). The median PFI was 28 months in the intermittent chemotherapy group, and 18 months in the control group (P = 0.0012).
Conclusion: It would be warranted to perform intermittent maintenance chemotherapy for patients with advanced ovarian cancer, if a clinically disease-free status could be achieved after completion of the standard treatment procedure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s101470200005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!